Testing conducted since 2016 has repeatedly demonstrated DehydraTECH has the ability to:
- Increase bio-absorption many-fold compared to standard industry formulations
- Reduce time of onset from 1 – 2 hours to minutes
- Deliver drugs more effectively across the blood brain barrier, and
- Improve tolerability
It is also being evaluated for hypertension, GLP-1 drugs and more.
Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many more patents pending worldwide.
Lexaria operates five subsidiary companies to focus on its different commercial opportunities in their respective industries:
- Lexaria Pharmaceutical Corp. investigates new pharmaceutical applications for hypertension, antiviral treatments, epilepsy and other drug classes
- Lexaria Nicotine LLC investigates oral non-combusted product formats
- Lexaria Hemp Corp. pursues business-to-business opportunities with hemp-derived ingredients
- Lexaria Canpharm ULC operates a state-of-the-art Health Canada licensed laboratory capable of developing novel cannabinoid and other formulations for potential commercialization
- Lexaria Nutraceutical Corp. explores applications of DehydraTECH for the consumer-packaged goods sector
Lexaria sub-licenses the Company’s DehydraTECH technology worldwide for the delivery of fat-soluble active molecules and drugs.
